Develop your research project in medicines, treatments and vaccines
© 2017 EPFL
The Innovative Medicines Initiative (IMI) is a European partnership between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) which aims to facilitate collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. The goal being to improve European citizens health and wellbeing by providing faster access to better medicines through identifying promising drug candidates with greater certainty at an early stage.
The first phase of the program started in 2008 until 2013 and had a budget of EUR 2 billion for over 50 projects which for some are still ongoing. The subjects of the IMI’s first phase are wide. Some focus on specific health issues such as neurological conditions (Alzheimer’s disease, schizophrenia, depression, chronic pain, and autism), diabetes, lung disease, oncology, inflammation & infection, tuberculosis, and obesity. Others focus on broader challenges in drug development like drug and vaccine safety, knowledge management, the sustainability of chemical drug production, the use of stem cells for drug discovery, drug behaviour in the body, the creation of a European platform to discover novel medicines, and antimicrobial resistance. In addition to research projects, IMI supports education and training projects.
The second phase of the program (IMI 2) has a EUR 3.3 billion budget for the period 2014-2024. The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics.
There are continuously calls until 2024, if you are interested in submitting a proposal, please have a look at the funding opportunities on our Research Funding Mémento.
For more information and help with your application, please contact the Research Office.
Source: European Commission (EC), European Federation of Pharmaceutical Industries and Associations (EFPIA) and Innovative Medicines Initiative (IMI) websites